Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or...
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
About this item
Full title
Author / Creator
Gelmon, Karen A, Prof , Tischkowitz, Marc, MD , Mackay, Helen, MD , Swenerton, Kenneth, MD , Robidoux, André, Prof , Tonkin, Katia, Prof , Hirte, Hal, MD , Huntsman, David, Prof , Clemons, Mark, MD , Gilks, Blake, Prof , Yerushalmi, Rinat, MD , Macpherson, Euan, MSc , Carmichael, James, MD and Oza, Amit, Prof
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background Olaparib (AZD2281) is a small-molecule, potent oral poly(ADP-ribose) polymerase (PARP) inhibitor. We aimed to assess the safety and tolerability of this drug in patients without BRCA1 or BRCA2 mutations with advanced triple-negative breast cancer or high-grade serous and/or undifferentiated ovarian cancer. Methods In this phase 2...
Alternative Titles
Full title
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_887160920
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_887160920
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(11)70214-5
